Journal of Oncology / 2019 / Article / Tab 1

Research Article

Portal Vein Embolization with PVA and Coils before Major Hepatectomy: Single-Center Retrospective Analysis in Sixty-Four Patients

Table 1

Patients’ characteristics.

Number of patients64
Age, mean (SD)63.84 (11.56)
Sex, N (%)
 Female19 (29.69)
 Male45 (70.31)
Tumor type, N (%)
 Hepatocellular carcinoma4 (6.25)
 Colangiocarcinoma12 (18.75)
 Colorectal metastases47 (73.44)
 Hydatid cyst1 (1.56)
Cirrhosis, N (%)
 Absent62 (96.88)
 Present2 (3.12)
Cirrhosis etiology, N (%)
 HCV1 (1.56)
 None identified63 (98.44)
Chemo before PVE, N (%)
 No23 (35.94)
 Yes41 (64.06)
Type of systemic chemotherapy, N (%)
 FOLFIRI9 (23.08)
 FOLFIRI + bevacizumab2 (5.13)
 FOLFIRI + cetuximab5 (12.82)
 FOLFIRI + panitumumab1 (2.56)
 FOLFIRINOX1 (2.56)
 FOLFOX6 (15.38)
 FOLFOX + bevacisumab2 (5.13)
 FOLFOX + cetuximab2 (5.13)
 FOLFOX + folfirinox1 (2.56)
 FOLFOX + folfirinox + cetuximab1 (2.56)
 XELOX + cetuximab1 (2.56)
 XELIRI1 (2.56)
 Xeloda + FOLFIRI + erbitux1 (2.56)
 XELOX3 (7.69)
 XELOX + bevacizumab2 (5.13)
 XELOX + XELIRI1 (2.56)
Chemo cycles, mean (SD)3.38 (4.36)
Biliary drainage before PVE, N (%)
 No63 (98.44)
 Yes1 (1.56)
Arterial embolization, N (%)
 No64 (100)

HCV: hepatitis C virus; PVE: portal vein embolization.